FDA says VasoCorp markets NeuropAWAY supplements as unapproved drugs with disease-treatment claims.
What happened
FDA reviewed www.vasocorp.com in March 2026 and found that VasoCorp takes orders there for NeuropAWAY and NeuropAWAY pm. FDA cited website claims that the products reduce, treat, or prevent nerve disease symptoms, making them drugs. FDA said the products are not generally recognized as safe and effective for those uses and are unapproved new drugs, and one product lacks adequate directions for use.
What FDA found
FDA says website claims that NeuropAWAY products reduce, treat, or prevent nerve disease make them drugs.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]FDA says the products are not generally recognized as safe and effective for those uses, making them unapproved new drugs.
section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]FDA says NeuropAWAY - Nerve Support Formula lacks adequate directions for safe use by a layperson for its intended disease use.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA says the misbranded drug is introduced or delivered for introduction into interstate commerce.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, including how it will prevent recurrence and related documentation. If corrective actions cannot be completed in that time, the company must state the reason for delay and when it will finish.
Who should pay attention
- dietary supplement companies making disease-related claims
- retail pharmacies selling nerve-support supplements
- consumers using supplements for neuropathy symptoms
This is a summary. Read the original letter on fda.gov.